A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed 13 enrolled University of Rochester

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and feasibility of the combination of decitabine given at a fixed dose with escalating doses of rapamycin in patients with relapsed or refractory acute myeloid leukemia.

Timeline

Start: 2010-01
Primary completion: 2012-09
Completion: —

Publications

Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL 2nd. A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leuk Res. 2013 Dec;37(12):1622-7. doi: 10.1016/j.leukres.2013.09.002. Epub 2013 Sep 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Decitabine	Small molecule	20 mg/m2	Intravenous
Subject	Sirolimus	Small molecule	2 mg	Oral
Subject	Sirolimus	Small molecule	4 mg	Oral
Subject	Sirolimus	Small molecule	6 mg	Oral

A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Summary

Timeline

Publications

Drugs

Indications